Select your city

Subscribe to Newsletter

GlobalNY.biz New York Business portal

8 September, Tuesday

1728

EUR/USD 1.16 GBP/USD 1.35

Brent 96.02 ▲ 7.0% Gas 2.90

Au 4 433.58 ▲ 0.8% Pt 207.79 ▲ 6.9%

Wheat 228.74 ▲ 14.6% Corn 213.19 ▲ 8.9%

BTC 78 798 ▼ 1.0% ETH 2 481.55 ▼ 0.6%

Company

Companies of New York

Mink Therapeutics

About
Rating
News
Persons

Subscribe to the company

Mink Therapeutics

Mink Therapeutics

Connections 2

Subscribe To favorites

Description

MiNK Therapeutics, Inc. is a biopharmaceutical company. The Company is specialized in discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress graft-versus-host-disease (GvHD).

The Company offers platform, which is designed for reproducible manufacturing for off-the-shelf delivery. Its product candidate, AGENT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy that is in multiple Phase I clinical trials, which is used for the treatment of multiple myeloma.

Website

https://www.minktherapeutics.com

Rating GlobalNY.biz

Take place №3016 In rating New York Organizations general
Take place №290 In rating Healthcare area

<!-- advertisement 10-->
<div class="mobileShow">
<script>
  atOptions = {
    'key' : '33fb986b72fdc254fb0c1e79be22e3ec',
    'format' : 'iframe',
    'height' : 250,
    'width' : 300,
    'params' : {}
  };
</script>
<script src="https://www.highperformanceformat.com/33fb986b72fdc254fb0c1e79be22e3ec/invoke.js"></script>
</div>
<div class="mobileHide">
<script>
  atOptions = {
    'key' : '60966449084d21264769e3d9bdff986a',
    'format' : 'iframe',
    'height' : 90,
    'width' : 728,
    'params' : {}
  };
</script>
<script src="https://www.highperformanceformat.com/60966449084d21264769e3d9bdff986a/invoke.js"></script>
</div>

18 March 2022

MiNK Therapeutics releases Q4 and full year 2021 results report

The company's financial results MiNK Therapeutics (NASDAQ: INKT) today released its financial resul...

MiNK Therapeutics releases Q4 and full year 2021 results report

14 March 2022

This week's company reports

Schedule for the week The US stock market closed Friday with a drop in prices as traders assessed t...

This week's company reports

<!-- advertisement 12-->
<div class="mobileShow">
<script type="text/javascript">
	atOptions = {
		'key' : '33fb986b72fdc254fb0c1e79be22e3ec',
		'format' : 'iframe',
		'height' : 250,
		'width' : 300,
		'params' : {}
	};
</script>
<script type="text/javascript" src="//www.highperformanceformat.com/33fb986b72fdc254fb0c1e79be22e3ec/invoke.js"></script>
</div>
<div class="mobileHide">
<script type="text/javascript">
	atOptions = {
		'key' : '60966449084d21264769e3d9bdff986a',
		'format' : 'iframe',
		'height' : 90,
		'width' : 728,
		'params' : {}
	};
</script>
<script type="text/javascript" src="//www.highperformanceformat.com/60966449084d21264769e3d9bdff986a/invoke.js"></script>
</div>

BALDONI John

Director of Mink Therapeutics
#1833
BEHNER Peter

Director of Mink Therapeutics
#1850
BUELL Jennifer

Director of Mink Therapeutics
#1870
CORVESE Brian

Director of Mink Therapeutics
#1888
RYAN Barbara

Director of Mink Therapeutics
#1907
WIINBERG Ulf

Director of Mink Therapeutics
#1925

Agenus

Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure can